SG Americas Securities LLC Has $336,000 Holdings in Biohaven Ltd. (NYSE:BHVN)

SG Americas Securities LLC cut its holdings in Biohaven Ltd. (NYSE:BHVN) by 45.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,001 shares of the company’s stock after selling 7,529 shares during the period. SG Americas Securities LLC’s holdings in Biohaven were worth $336,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. ARS Investment Partners LLC boosted its stake in shares of Biohaven by 1.0% during the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock worth $38,871,000 after acquiring an additional 10,473 shares in the last quarter. Weybosset Research & Management LLC lifted its holdings in Biohaven by 23.9% in the 4th quarter. Weybosset Research & Management LLC now owns 13,645 shares of the company’s stock worth $510,000 after purchasing an additional 2,635 shares during the last quarter. Diversified Trust Co boosted its position in Biohaven by 16.6% during the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after purchasing an additional 795 shares during the period. JPMorgan Chase & Co. boosted its position in Biohaven by 85.4% during the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after purchasing an additional 372,737 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Biohaven by 0.5% during the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock valued at $4,206,000 after purchasing an additional 412 shares during the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Trading Up 4.2 %

Shares of BHVN stock opened at $39.30 on Wednesday. The company has a market capitalization of $3.97 billion, a P/E ratio of -4.20 and a beta of 1.28. Biohaven Ltd. has a 12 month low of $26.80 and a 12 month high of $62.21. The stock has a 50 day moving average of $39.34 and a two-hundred day moving average of $42.61.

Biohaven (NYSE:BHVN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.03). Sell-side analysts predict that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Insider Transactions at Biohaven

In related news, Director John W. Childs bought 29,000 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the transaction, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 16.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BHVN shares. TD Cowen boosted their price objective on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price target (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Finally, HC Wainwright reissued a “buy” rating and set a $59.00 price objective on shares of Biohaven in a research report on Tuesday, December 17th. Thirteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $63.00.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.